Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price ...

And why didn’t it cut off Russia’s natural gas earlier? By Marc SantoraAndrew Higgins and Stanley Reed A transnational pipeline was shut down on Wednesday after Kyiv refused to renew a ...

In New Orleans, Celebration Is Followed by Terror in the French Quarter The attack left 15 dead and about three dozen injured. The authorities described it as an act ...

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.